New Body Blow For Aducanumab As Japan Asks For More Data
Executive Summary
Request for additional data after a surprise review committee meeting sets back approval in potentially large market, adding to Biogen and Eisai’s woes following the recent EU negative opinion and poor performance and price cut in the US.
You may also be interested in...
Biogen Pledges Aduhelm Confirmatory Data By 2026, Renewing Spotlight On FDA’s Lengthy Original Plan
Biogen's update on the timeline for running a confirmatory study of the Alzheimer's treatment is much faster than the nine years required by US FDA under the accelerated approval.
Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price
The first disease modifying drug for Alzheimer's disease will be priced at a $56,000 a year for an average weight patient, setting the drug up to be a mega blockbuster if Biogen can get it reimbursed.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.